About ViAqua
ViAqua is a company based in Rehovot (Israel) founded in 2014 by Shai Ufaz and Shai Einbinder. ViAqua has raised $12.55 million across 5 funding rounds from investors including Nutreco, The Trendlines Group and Thai Union Group. ViAqua offers products and services including RNAi Delivery Platform. ViAqua operates in a competitive market with competitors including Sirnaomics, Arcturus Therapeutics, Vaxxas, Topas Therapeutics and Ensysce, among others.
- Headquarter Rehovot, Israel
- Founders Shai Ufaz, Shai Einbinder
-
Sectors
TechnologyAgriculture
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Viaqua Therapeutics Ltd
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$12.55 M (USD)
in 5 rounds
-
Latest Funding Round
$8.25 M (USD), Series A
Sep 05, 2023
-
Investors
Nutreco
& 8 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ViAqua
ViAqua offers a comprehensive portfolio of products and services, including RNAi Delivery Platform.
Encapsulated RNA in feed for preventing viral diseases in shrimp.
People of ViAqua
Unlock access to complete
Unlock access to complete
Funding Insights of ViAqua
ViAqua has successfully raised a total of $12.55M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $8.25 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series A — $8.2M
- First Round First Round
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2023 | Amount | Series A - ViAqua | Valuation | S2G Ventures | |
| Jun, 2021 | Amount | Series A - ViAqua | Valuation | S2G Ventures | |
| Dec, 2018 | Amount | Series A - ViAqua | Valuation |
investors |
Investors in ViAqua
ViAqua has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Nutreco, The Trendlines Group and Thai Union Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Stage agnostic venture capital firm
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Venture capital fund and startup incubator for healthcare and agricultural companies
|
Founded Year | Domain | Location |
Investments & Acquisitions by ViAqua
Financial Statements - ViAqua
Viaqua Comparisons
Competitors of ViAqua
ViAqua operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sirnaomics, Arcturus Therapeutics, Vaxxas, Topas Therapeutics and Ensysce, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
RNA-based therapeutics for cancer and fibrosis are developed.
|
|
| domain | founded_year | HQ Location |
RNAi technologies are developed for treating rare orphan diseases.
|
|
| domain | founded_year | HQ Location |
Developer of vaccines to treat cancer and infectious diseases
|
|
| domain | founded_year | HQ Location |
Nanoparticle-based therapeutics for immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Drug delivery solutions via single-walled carbon nanotubes are offered.
|
Latest news on Viaqua
Frequently Asked Questions about ViAqua
ViAqua was founded in 2014 and raised its 1st funding round 2 years after it was founded.
ViAqua is headquartered in Rehovot, Israel. It is registered at Rehovot, Central District, Israel.
Shai Ufaz is the current CEO of ViAqua. They have also founded this company.
ViAqua is a funded company, having raised a total of $12.55M across 5 funding rounds to date.
ViAqua was founded in 2014 in Rehovot, Israel, focusing on the aquaculture sector. RNAi nanoparticle formulations are developed as a drug delivery platform for oral or immersion administration. Treatments are designed to halt disease progression and prevent viral outbreaks in aquatic species. Cellular responses are triggered by the technology to neutralize infections, with delivery occurring through feed integration or direct immersion methods.
ViAqua's top competitors include Sirnaomics, Arcturus Therapeutics and Splice Bio.
ViAqua offers RNAi Delivery Platform.
ViAqua has 9 investors. Key investors include Nutreco, The Trendlines Group, Thai Union Group, Technion - Israel Institute of Technology, and Israel Innovation Authority.